10 June 2022
RUSNANO has stopped the withdrawal from a number of critically important assets for the country, which contribute to the provision of infrastructure and form a technological reserve for the Russian industry in mechanical engineering, medicine, chemistry, oil and gas, lighting and electronics, telecommunications, energy, transport and housing. Among them are the companies "Plakart", "Virial", "Optical Fiber Systems", "RM Nanotech", "Profotek", "Russian Quartz", "NEVZ-CERAMICS", "Novomet", "ELVIS NeoTek", "ICE-Energoservice", "NovaMedica", "Pharmsintez" and a number of projects of the RUSNANO-SINTEZ Foundation.
26 April 2022
Technopolis Moscow has begun the production of a new therapy for dementia in Alzheimer’s disease, available in the form of tablets in four dosages. This is reported on the official website of the mayor of Moscow.
21 April 2022
NovaMedica, a Russian pharmaceutical company (Rusnano’s investment project) has developed and registered an innovative combination of donepezil and memantine molecules, which provides the basis for dementia therapy in Alzheimer’s disease. The drug is registered as MYOREOL®. This is the first combination of this type on the Russian market, as well as in the EAEU and Europe.
28 September 2021
Excessive regulation of the Russian pharmaceutical market and the lack of drug insurance system is leading to a shortage of some vital and effective drugs in the local market, according to recent statements by representatives of producers and analysts.
26 July 2021
NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.
31 May 2021
Concern Bayer will expand its portfolio of drugs for the treatment of hemorrhoids with the development of the Russian “NovaMedica” based on nifedipine and lidocaine. The German company already holds about 40% of the market for such funds. Pharmaceutical market experts call the deal one of the rare ones: foreign companies do not often acquire rights to Russian medicines.
29 July 2019
Major Russian pharmaceutical company NovaMedica and the US-based Unipharm have launched a joint project to localize in Russia the production of Melaxen®, a hormone secreted by the pineal gland in a 24-hour circadian rhythm, regulating the normal sleep/wake cycle. Production capacity expected to reach hundreds of thousands of packages per year. It will be enough to meet the requirements of patients living in the territory of the EAEU.
23 July 2019
The Russian pharmaceutical market is considered to be one of the most dynamic ones. In recent years, the annual growth is about 10%. The state policy that stimulates the production localization is effectively implemented. A new investment instrument has been launched in Russia – a special investment contract (SPIC). On March 7, 2018, NovaMediña, a portfolio company of RUSNANO, concluded the largest in the pharmaceutical industry a special investment contract (SPIC) with the Russian Federation represented by the Ministry of Industry and Trade of Russia and the Kaluga Region to establish the production of sterile injectable dosage forms.
19 June 2019
Russian drug companies NovaMedica and Pharmsynthez have launched a joint project to make a number of effective drugs available to Russian patients within 1.5-2 years. Integrated local production of these drugs will be set up in Russia, RUSNANO informed.
18 April 2019
Si quiere atraer a un socio internacional (proveedor) para localizar en su empresa sus productos, debe seguir con exactitudm las normas internacionales. Conocer y ser capaz de realizar transferencia correctamente. Al parecer, no hay de que discutir. Pero aun, prevalecen los antiguos enfoques en la organization de transferencia de tecnologias farmaceuticas: "Escribannos los componentes, y nosotros lo dominaremos todo aqui por nuestra cuenta".
09 December 2022
08 December 2022
08 December 2022
07 December 2022